{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:54:52Z","timestamp":1758992092805},"reference-count":97,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.cld.2005.07.009","type":"journal-article","created":{"date-parts":[[2005,10,4]],"date-time":"2005-10-04T18:23:10Z","timestamp":1128450190000},"page":"647-666","source":"Crossref","is-referenced-by-count":6,"title":["HIV and Liver Diseases: Recent Clinical Advances"],"prefix":"10.1016","volume":"9","author":[{"given":"Cem","family":"Cengiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas T.","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2005.07.009_bib1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","article-title":"Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross sectional analysis of the US adult AIDS Clinical Trials Group","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus infection and hepatitis C virus coinfected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2005.07.009_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2893.2000.00230.x","article-title":"Hepatitis C is more severe in drug users with human immunodeficiency virus infection","volume":"7","author":"Romeo","year":"2000","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cld.2005.07.009_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/jhep.2001.26517","article-title":"Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus coinfected patients: impact of protease inhibitor therapy","volume":"34","author":"Benhamou","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2005.07.009_bib5","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/00002030-200411190-00009","article-title":"Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome","volume":"18","author":"Puoti","year":"2004","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.cld.2005.07.009_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1572-0241.2001.03374.x","article-title":"Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C","volume":"96","author":"Garcia-Samaniego","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2005.07.009_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality in end stage liver disease in patients with human immunodeficiency virus infection","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib8","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/hep.1840200508","article-title":"Hepatitis C in HIV infected patients with and without AIDS: prevalence and relationship to patient survival","volume":"20","author":"Wright","year":"1994","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2005.07.009_bib9","first-page":"1212A","article-title":"HIV\u2013HCV coinfected patients followed prospectively for a mean of 4.2 years, have similar rates of death or cirrhosis compared to HCV mono-infected patients","volume":"40","author":"Monto","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2005.07.009_bib10","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","article-title":"Clinical progression, survival, and immune recovery during anti retroviral therapy in patients with HIV-1 and hepatitis c virus coinfection: the Swiss HIV Cohort Study","volume":"357","author":"Greub","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2005.07.009_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.288.2.199","article-title":"Hepatitis C and progression of HIV disease","volume":"288","author":"Sulkowski","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2005.07.009_bib12","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1001\/archinte.160.22.3365","article-title":"Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues","volume":"160","author":"Bonacini","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cld.2005.07.009_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa -2a plus ribavirin versus interferon alfa 2a plus ribavirin for chronic hepatitis C in HIV coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2005.07.009_bib14","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b versus standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2005.07.009_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2005.07.009_bib16","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(00)04920-5","article-title":"Mitochondrial toxic effects and ribavirin","volume":"357","author":"Kakuda","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2005.07.009_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1086\/376971","article-title":"Hematological disorders associated with hepatitis C virus infection and their management","volume":"37","author":"Dieterich","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib18","unstructured":"Sulkowski M.S., Felizarta F., Slim J., et al. Final results of daily vs. 3 times weekly interferon alfa 2b plus ribavirin for the treatment of hepatitis C infection in HIV-infected persons: a multi-center randomized open-label study. Presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, February 11, 2003"},{"key":"10.1016\/j.cld.2005.07.009_bib19","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1097\/00002030-200208160-00024","article-title":"Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV\/hepatitis C virus coinfected individuals","volume":"16","author":"Taylor","year":"2002","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.cld.2005.07.009_bib20","first-page":"A386","article-title":"Low physician referral rates and high no-show rates are major barriers to HCV therapy among patients coinfected with HCV and HIV","volume":"40","author":"Shim","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2005.07.009_bib21","first-page":"S3","article-title":"Management of hepatitis C: 2002","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2005.07.009_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jmv.2203","article-title":"Intrahepatic HCV RNA loads in 37 HIV\u2013HCV coinfected patients with controlled HIV infections","volume":"67","author":"Trimoulet","year":"2002","journal-title":"J Med Virol"},{"key":"10.1016\/j.cld.2005.07.009_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00126334-200306010-00005","article-title":"Pretreatment of chronic active hepatitis C in patients coinfected with HIV and HCV reduces the hepatotoxicity associated with subsequent antiretroviral therapy","volume":"33","author":"Uberti-Foppa","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cld.2005.07.009_bib24","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Hepatitis B virus infection","volume":"337","author":"Lee","year":"1997","journal-title":"N Engl J Med"},{"issue":"3A","key":"10.1016\/j.cld.2005.07.009_bib25","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/0002-9343(89)90523-8","article-title":"Seroepidemiology of hepatitis B virus infection in the United States. 1976 to 1980","volume":"87","author":"McQuillan","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.cld.2005.07.009_bib26","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J","article-title":"Hepatitis B virus: the major etiology of hepatocellular carcinoma","volume":"61","author":"Beasley","year":"1988","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.cld.2005.07.009_bib27","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2105\/AJPH.80.12.1475","article-title":"Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection","volume":"80","author":"Solomon","year":"1990","journal-title":"Am J Public Health"},{"key":"10.1016\/j.cld.2005.07.009_bib28","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/hep.510290447","article-title":"Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men","volume":"29","author":"Colin","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2005.07.009_bib29","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2005.07.009_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-2003-39944","article-title":"Human immunodeficiency virus and liver: lessons learned and still to be learned","volume":"23","author":"Dieterich","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib31","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1128\/JCM.37.9.3013-3016.1999","article-title":"Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus","volume":"37","author":"Thibault","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cld.2005.07.009_bib32","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1572-0241.2002.05819.x","article-title":"Nucleoside analogues for chronic hepatitis B: Antiviral efficacy and viral resistance","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2005.07.009_bib33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2005.07.009_bib34","first-page":"S3","article-title":"EASL International Consensus Conference on Hepatitis B. 13\u201314 September, 2002 Geneva, Switzerland. Consensus statement (long version)","volume":"39","author":"de Franchis","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2005.07.009_bib35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0016-5085(03)00939-9","article-title":"Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV DNA polymerase","volume":"125","author":"Angus","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2005.07.009_bib36","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(01)05840-8","article-title":"Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label study","volume":"358","author":"Benhamou","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2005.07.009_bib37","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/AAC.46.5.1586-1588.2002","article-title":"Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine","volume":"46","author":"Delaugerre","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2005.07.009_bib38","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1097\/00002030-200211220-00023","article-title":"Activity of tenofovir on hepatitis B virus replication in HIV-coinfected patients failing or partially responding to lamivudine","volume":"16","author":"Nunez","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0163-4453(03)00082-3","article-title":"Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir","volume":"47","author":"Callens","year":"2003","journal-title":"J Infect"},{"key":"10.1016\/j.cld.2005.07.009_bib40","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1086\/345770","article-title":"Tenofivir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus\/hepatitis B virus-coinfected individuals for whom interferon-a and lamivudine therapy have failed","volume":"186","author":"Ristig","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1056\/NEJM200301093480218","article-title":"Tenofivir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus","volume":"348","author":"Benhamou","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2005.07.009_bib42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepat"},{"issue":"9454","key":"10.1016\/j.cld.2005.07.009_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2005.07.009_bib44","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/00002030-199810000-00025","article-title":"Hepatotoxicity after introduction of highly active antiretroviral therapy","volume":"12","author":"Rodriguez-Rosado","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis B or C virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2005.07.009_bib46","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00042560-200108150-00002","article-title":"Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy","volume":"27","author":"Nunez","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cld.2005.07.009_bib47","unstructured":"Reisler R., Servoss J.C., Sherman K.E., et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials: ACTG Liver Diseases Focus Group [abstract 43]. Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires (Argentina): 2001. p. 94"},{"key":"10.1016\/j.cld.2005.07.009_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/341084","article-title":"Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy","volume":"186","author":"Wit","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib49","doi-asserted-by":"crossref","first-page":"F115","DOI":"10.1097\/00002030-199912030-00002","article-title":"Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996\u20131998. Groupe d'Epidemiologie Clinique de Sida en Aquitaine (GECSA)","volume":"13","author":"Saves","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0168-8278(99)80020-8","article-title":"Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion","volume":"30","author":"Chariot","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2005.07.009_bib51","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/00002030-200104130-00007","article-title":"Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy","volume":"15","author":"John","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib52","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/324353","article-title":"Hyper-lactatemia and antiretroviral therapy: the Swiss HIV Cohort Study","volume":"33","author":"Boubaker","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib53","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/339041","article-title":"Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature","volume":"34","author":"Falco","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib54","doi-asserted-by":"crossref","first-page":"40847","DOI":"10.1074\/jbc.M106743200","article-title":"Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase","volume":"276","author":"Johnson","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cld.2005.07.009_bib55","doi-asserted-by":"crossref","first-page":"F197","DOI":"10.1097\/00002030-199816000-00001","article-title":"A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-na\u00efve subjects","volume":"12","author":"Staszewski","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib56","doi-asserted-by":"crossref","first-page":"F203","DOI":"10.1097\/00002030-199816000-00002","article-title":"Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults","volume":"12","author":"Saag","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib57","first-page":"1153","article-title":"Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures-worldwide, 1997\u20132000","volume":"49","author":"Boxwell","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cld.2005.07.009_bib58","first-page":"511","article-title":"Hepatic safety with nevirapine (NVP) and two nucleosides in patients with advanced HIV infection, from a placebo (PBO)-controlled clinical endpoint trial (1090)","volume":"14","author":"Cahn","year":"2000","journal-title":"AIDS"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2005.07.009_bib59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/381447","article-title":"Liver toxicity in epidemiological cohorts","volume":"38","author":"Becker","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2005.07.009_bib60","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1086\/381450","article-title":"Drug-induced liver injury associated with the use of non-nucleoside reverse-transcriptase inhibitors","volume":"38","author":"Dieterich","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib61","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2005.07.009_bib62","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","article-title":"Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy","volume":"15","author":"Martinez","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib63","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine and efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2005.07.009_bib64","unstructured":"Dieterich D.T., Stern J., Robinson P., et al. Analyses of 4 key clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4 + levels, hepatitis B&C seropositivity and baseline liver function tests. Presented at the 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires (Argentina), July 8\u201311, 2001"},{"key":"10.1016\/j.cld.2005.07.009_bib65","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00042560-200201010-00005","article-title":"Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection","volume":"29","author":"Aceti","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cld.2005.07.009_bib66","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/AAC.45.12.3393-3402.2001","article-title":"Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients","volume":"45","author":"Michelet","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2005.07.009_bib67","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/339867","article-title":"Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus","volume":"34","author":"Cooper","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib68","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1097\/00002030-200411190-00008","article-title":"Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir","volume":"18","author":"Sulkowski","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib69","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(05)62892-9","article-title":"Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor","volume":"349","author":"Carr","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2005.07.009_bib70","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1097\/00002030-199817000-00010","article-title":"Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?","volume":"12","author":"John","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib71","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2005.07.009_bib72","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ajcp\/83.5.582","article-title":"Clinical and pathologic findings of the liver in the acquired immunodeficiency syndrome (AIDS)","volume":"83","author":"Glasgow","year":"1985","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cld.2005.07.009_bib73","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ajcp\/81.5.549","article-title":"Acquired immunodeficiency syndrome: postmortem findings","volume":"81","author":"Guarda","year":"1984","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cld.2005.07.009_bib74","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1440-1746.1999.01820.x","article-title":"Findings and benefit of liver biopsies in 46 patients infected with human immunodeficiency virus","volume":"14","author":"Piratvisuth","year":"1999","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2005.07.009_bib75","first-page":"43","article-title":"Consequences for the management of cytomegalovirus","volume":"10","author":"Katlama","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/14787210.2.1.27","article-title":"Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts","volume":"2","author":"Razonable","year":"2004","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cld.2005.07.009_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jmv.10163","article-title":"Prolonged hepatitis A infection in an HIV-1 seropositive patient","volume":"68","author":"Costa-Mattioli","year":"2002","journal-title":"J Med Virol"},{"key":"10.1016\/j.cld.2005.07.009_bib78","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/338152","article-title":"Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection","volume":"34","author":"Ida","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/135965350000500107","article-title":"Persisting HIV-1 replication triggered by acute hepatitis A infection","volume":"5","author":"Ridolfo","year":"2000","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cld.2005.07.009_bib80","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa003364","article-title":"Effect of coinfection with GB virus C (hepatitis G virus) on survival among patients with HIV infection","volume":"345","author":"Xiang","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2005.07.009_bib81","unstructured":"Xiang J., George S.L., Wuenschmann S, et al. GBV-C infection inhibits CCR5 and CXCR4 HIV strains, and alters chemokine and cytokine gene expression in PBMC cultures. Presented at the Conference on Retroviruses and Opportunistic Infections. Boston, February 12, 2003"},{"key":"10.1016\/j.cld.2005.07.009_bib82","doi-asserted-by":"crossref","unstructured":"Nunnari G., Nigro L., Palermo F., et al. Slower progression of HIV-1 infection in HGV\/GB virus C co-infected individuals correlates with an intact T helper 1 cytokine profile. Presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle (WA), February 24\u201328, 2002","DOI":"10.7326\/0003-4819-139-1-200307010-00009"},{"key":"10.1016\/j.cld.2005.07.009_bib83","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM200201313460518","article-title":"GB virus C and mortality from HIV infection","volume":"346","author":"Mosier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2005.07.009_bib84","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00042560-200107010-00005","article-title":"Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy","volume":"27","author":"Duong","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2005.07.009_bib85","first-page":"348A","article-title":"Correlation of insulin resistance with steatosis and fibrosis in hepatitis C and HIV coinfection: Cross-sectional analysis of 101 patients","volume":"40","author":"Agarwal","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2005.07.009_bib86","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.284.4.472","article-title":"Metformin in the treatment of HIV lipodystrophy syndrome","volume":"284","author":"Hadigan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2005.07.009_bib87","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00002030-199905280-00023","article-title":"Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib88","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00126334-200210010-00006","article-title":"Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study","volume":"31","author":"Gelato","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cld.2005.07.009_bib89","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/00002030-200303280-00022","article-title":"Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy","volume":"17","author":"Calmy","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib90","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/317426","article-title":"Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy","volume":"31","author":"Martinez","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2005.07.009_bib91","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/00002030-200109280-00010","article-title":"HIV protease inhibitor substitution in patients with lipodystrophy: a randomised controlled, open-label, multi-centre study","volume":"15","author":"Carr","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2005.07.009_bib92","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2005.07.009_bib93","doi-asserted-by":"crossref","first-page":"63S","DOI":"10.1002\/hep.1840200714","article-title":"Consensus statement on indication for liver transplantation: Paris. June 22\u201323, 1993","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2005.07.009_bib94","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00007890-199002000-00025","article-title":"Transplantation in HIV-positive patients","volume":"49","author":"Tzakis","year":"1990","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2005.07.009_bib95","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/lt.20318","article-title":"Liver transplantation in HIV infected recipients","volume":"11","author":"Moreno","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2005.07.009_bib96","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/lt.20233","article-title":"Outcomes of liver transplantation in HIV infected individuals: The impact of HCV and HBV infection","volume":"10","author":"Norris","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2005.07.009_bib97","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1086\/379254","article-title":"Survival of human immunodeficiency virus-infected liver transplant recipients","volume":"188","author":"Ragni","year":"2003","journal-title":"J Infect Dis"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932610500070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932610500070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T23:06:03Z","timestamp":1683241563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932610500070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S108932610500070X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2005.07.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}